[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-breast-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,77,112,147,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100626472","culturally-adapting-an-intervention-to-increase-genetic-testing-in-african-american-cancer-survivors-100626472",false,"NCT07436078","Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors","A Community-Engaged Approach to Culturally Adapting an Intervention to Increase Uptake of Genetic Testing Among African American Cancer Survivors","Inclusion Criteria:\n\n* Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS)\n* Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1\u002F1\u002F2013\n* have received or currently receiving care at Karmanos Cancer Institute\n* meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below\n\nFemale breast\n\n1. personal diagnosis at age ≤50\n2. personal history of the triple-negative subtype\n3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \\\u003C50\n4. at least 1 close relative diagnosed with ovarian cancer\n5. 2+ close relatives diagnosed with breast or prostate cancer\n6. age \\\u003C50 AND another primary breast cancer at any age\n7. 2+ primary breast cancers at any age\n\nOR Prostate\n\n1. personal history of high-risk or very high-risk prostate cancer\n2. personal history of regional or metastatic prostate cancer\n3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \\\u003C60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer)\n\nOR Colorectal\n\n1. personal diagnosis at age ≤50\n2. at least 1 close relative diagnosed with HNPCC at age \\\u003C50\n3. at least 2 close relatives diagnosed with an HNPCC cancer at any age\n4. colorectal and \\>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate\n\nExclusion Criteria:\n\n* Previous genetic counseling and\u002For testing","ALL","20 Years","79 Years",{"count":20,"type":21},85,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African Americans at risk for heredity cancers. With the help of community stakeholders and clinical genetic professionals the investigators will:\n\n* adapt and refine a culturally relevant online educational genetic counseling program for at-risk African Americans\n* Test the effects of the educational program\n* collaborate with community leaders and clinical genetic professionals to translate study findings, develop a road map for dissemination to the community, and identify barriers to prepare for future trials.\n\nParticipants from Detroit Research on Cancer Survivor group will be offered enrollment. Once consent is obtained, questionnaires will be completed before an online genetic counselling intervention immediately after, and at 3 months",[27,28,29],"Female Breast Cancer","Prostate Cancer","Colorectal Carcinoma","RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2026-04-18",{"date":38,"type":21},"2029-07",{"name":40,"class":41},"Barbara Ann Karmanos Cancer Institute","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100523228","phase-2-iit2023-09-chung-upfronttad-upfront-tadsnb-in-patients-with-breast-cancer-with-nodal-metastases-100523228","NCT06092892","IIT2023-09-Chung-UpfrontTAD: Upfront TAD\u002FSNB in Patients With Breast Cancer With Nodal Metastases","IIT2023-09-Chung-UpfrontTAD: Upfront TAD\u002FSNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases","Inclusion Criteria:\n\n* Women age ≥ 45\n* Clinical T1-2N0 ER+ invasive breast cancer\n* US detected biopsy proven axillary nodal disease\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Palpable nodes on physical exam\n* Her2+ or ER- invasive breast cancer\n* Extranodal extension \\> 3 mm on nodal biopsy\n* More than 2 suspicious nodes on preoperative imaging","FEMALE","45 Years",{"count":53,"type":21},45,[55],"PHASE2","The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+\u002FHer2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.",[58,59,27,60,61,62],"Breast Cancer","Axillary Nodal Disease","Axilla; Breast","Mastectomy; Lymphedema","Tumor, Breast",[64,65,66],"T1-2N0 ER+ invasive","biopsy","upfront lumpectomy","2026-05-06",{"date":69,"type":34},"2026-05-11",{"date":71,"type":34},"2024-04-07",{"date":73,"type":21},"2031-04",{"name":75,"class":41},"Alice Chung",3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":50,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100500122","proofs-registry---premenopausal-women-with-breast-cancer-optimally-treated-with-ofs-100500122","NCT05792150","PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS","Real World Data and Long-term FU of Pre-\u002FPerimenopausal Women With Luminal EBC With Intermediate to High Clinical and Low Genomic Recurrence-risk Measured by MammaPrint®, Treated by SOC ET+OFS or SOC Chemotherapy Treatment Followed by ET","PROOFS","Inclusion Criteria:\n\nPatients are eligible for participation in the registry only if they meet all the following criteria:\n\n* Female breast cancer patients\n* Pre- or perimenopausal at registry entry (age \\\u003C60 years and state after hysterectomy or amenorrhea for \\\u003C12 months; confirmation by blood hormone levels (FSH and estradiol in premenopausal range as per local normal range) recommended)\n* Primary tumor diagnosis not older than three months prior to inclusion (primary diagnosis defined as date of initial tumor biopsy)\n* Estrogen- and\u002For progesterone-receptor-positive\u002FHER2 negative early breast cancer without any clinical signs of metastases\n* Adequate risk for recurrence:\n* intermediate clinical risk for recurrence, defined as (clinical in case of neoadjuvant treatment):\n* c\u002FpT1 and\n* c\u002FpN0 and\n* Ki-67 15-24% or\n* G2 or\n* patients, who do not meet these criteria but are at intermediate clinical risk for recurrence at investigator decision (e.g., very young age, low expression of hormone receptors, existing co-morbidities, familial cancer burden, etc.) can be included on individual decision basis or\n* high clinical risk for recurrence, defined as either (clinical in case of neoadjuvant treatment):\n* c\u002FpT2-4 or\n* c\u002FpN1 or\n* Ki-67 ≥25% or\n* G3\n* Low genomic risk of recurrence by MammaPrint® (tested on treatment naïve tumor specimen)\n* Luminal-type by BluePrint®\n* Treatment according to standard-of-care (e.g., AGO Guidelines) planned or started (until completion of local therapy the latest (including started or completed endocrine induction therapy), started, or planned adjuvant or neoadjuvant treatment)\n* Availability of untreated tumor material (core biopsy if preoperative endocrine therapy performed or neoadjuvant treatment intended or surgery specimen)\n* Capability to give written informed consent\n* Nodal positive patients will be accepted to the registry up to 25% of the genomic low\u002Fultralow-risk population (n=441).\n\nExclusion Criteria:\n\nPatients will not be eligible for the registry for any of the following reasons:\n\n* Any other genomic testing, besides MammaPrint®, has been performed on the tumor material\n* Medical or psychological conditions that would not permit the patient to sign informed consent\n* Legal incapacity or limited legal capacity\n* Current participation in any interventional clinical trial which tests anticancer drugs, immunotherapeutics, or antibody treatment for any type of neoplasm\n* Non-compliance of the patient","18 Years","60 Years",{"count":88,"type":21},1470,"10 Years","OBSERVATIONAL","There is only limited data for premenopausal patients in general, as well as for differences in the use of OFS in the subgroups of pre- and perimenopausal patients, respectively. The WSG ADAPT trial data on the impact of postmenopausal status and\u002For use of OFS within 3-4 weeks endocrine induction therapy show relevant impact of OFS\u002Fpostmenopausal status on Ki-67 response; also, secondary amenorrhea after (neo-)adjuvant chemotherapy was a positive predictor of outcome due to OFS \\[8, 9\\].\n\nThis registry will give insights in the real-world use of OFS and the effect of secondary amenorrhea in female pre- and perimenopausal patients with or without previous use of chemotherapy and with different endocrine treatments (ET +\u002F- GnRH).\n\nAs adherence over time (5-10 years) plays a major role in the endocrine treatment, the registry will follow patients' treatments for up to 10 years and include QoL information.\n\nResults of MammaPrint® (MammaPrint® Index) as indicating factor for chemotherapy use and risk classification, thus, choice of adjuvant treatment (chemotherapy, OFS combined with endocrine therapy, or endocrine therapy alone) will be correlated to outcome under real-world conditions.\n\nBaseline, treatment, and relapse data shall be collected to gain further insight in the treatment paths, treatment adherence, and outcome of such patients.",[27],[94,95,96,97,98,99,100,101],"HR+","HER2-","EBC","early breast cancer","female","OFS","ET","chemotherapy","2026-01-22",{"date":104,"type":34},"2026-01-26",{"date":106,"type":34},"2022-12-07",{"date":108,"type":21},"2035-06",{"name":110,"class":41},"West German Study Group",71,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":50,"minAge":85,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":124,"conditions":125,"keywords":130,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100527161","phase-3-a-study-of-a-comprehensive-prevention-program-to-reduce-lymphedema-after-axillary-lymph-node-dissection-in-people-with-breast-cancer-100527161","NCT06144164","A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer","A Prospective Cohort Study of Patients Undergoing ALND for Treatment of Breast Cancer: The Efficacy of a Comprehensive Prevention Program in Decreasing the Incidence of Lymphedema and Improving Quality of Life","Inclusion Criteria:\n\n* Female sex\n* Diagnosis of breast cancer\n* Ages 18 to 75 years\n* Consented for unilateral ALND or for unilateral SLNB with possible ALND\n\nExclusion Criteria:\n\n* Male sex\n* Does not speak English\n* Does not fit into study garment\n* Axillary recurrence\n* History of ALND\n* Requirement of bilateral ALND for the treatment of breast cancer\n* Treatment with SLNB only\n* Known anaphylactic allergy to ICG dye used in ILR\n* Impaired decision-making capacity","75 Years",{"count":121,"type":21},285,[123],"PHASE3","The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.",[126,127,128,58,129,27],"Lymphedema","Lymphedema Arm","Lymphedema of Upper Arm","Breast Carcinoma",[131,132,126,127,128,133,134,135,136,137],"immediate lymphatic reconstruction","axillary lymph node dissection","Breast cancer","breast carcinoma","female breast cancer","Memorial Sloan Kettering Cancer Center","23-303","2025-11-06",{"date":140,"type":34},"2025-11-10",{"date":142,"type":34},"2023-11-16",{"date":144,"type":21},"2030-03-16",{"name":136,"class":41},7,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":50,"minAge":86,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":42},"100569602","melatonin-supplementation-and-exercise-program-in-breast-cancer-women-100569602","NCT06696378","Melatonin Supplementation and Exercise Program in Breast Cancer Women","Impact of Melatonin Supplementation Plus Exercise Program in Women Who Have Suffered from Breast Cancer in the Province of Soria, Spain","MEXBSO","Inclusion Criteria:\n\n* Study participants were women with a history of ductal carcinoma in situ, lobular carcinoma in situ, or stage 1 to 3 breast cancer (5 years or more since diagnosis), not currently receiving chemotherapy or hormone therapy, postmenopausal, and Eastern Cooperative Oncology Group (ECOG) score ≤ 1\n\nExclusion Criteria:\n\n* women who had exercised regularly for at least 20 minutes once and at least twice a week in the 3 months before the study\n* Stage IV breast cancer or systemic recurrences\n* Known autoimmune diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis.\n* Severe kidney disease\n* Use of adjuvant hormonal therapy, oral estrogen or progesterone replacement therapy, luteinizing hormone-releasing hormone agonists currently or within the past 60 days\n* 6-month ≥ post-chemotherapy\n* Concomitant use of sleeping pills every night at bedtime\n* Concomitant use of black cohosh, flaxseed, or soy in pill or supplement form\n* Functional limitation using the Barthel scale (less than 100 = maximum score) and the Lawton-Brody scale (less than 8 = maximum value).\n* Uncontrolled hypertension (\\>180\u002F100 mm Hg).\n* Uncontrolled atrial or ventricular arrhythmias, dissecting aortic aneurysm, severe aortic stenosis, acute endocarditis\u002Fpericarditis\n* Acute thromboembolic disease.\n* Moderate\u002Fsevere chronic obstructive pulmonary disease (COPD) with Bodex index C or D Recent bone fracture (last month).\n* Any other circumstance that your doctor considers prevents physical activity.\n* Neoadjuvant chemotherapy or radiotherapy\n* Concomitant use of beta-blockers\n* 6-month ≥ post-radiotherapy\n* Concomitant use of postmenopausal hormone replacement therapy\n* Use of any type of oral melatonin supplement in the past 30 days\n* Acute\u002Fchronic heart failure with NYHA (New York Heart Association) score \\>II\n* Uncontrolled orthostatic hypotension\n* Recent acute myocardial infarction (3 to 6 months) or unstable angina.\n* Acute\u002Fchronic respiratory failure.\n* Diabetes mellitus with acute decompensation or uncontrolled hypoglycemia\n* History of dementia (suspected by the GP environment and diagnosed).\n* Shift-work and night-work","80 Years",{"count":157,"type":21},120,[24],"Introduction: Breast cancer (BC) remains the leading cause of cancer in women with nearly 1.4 million new cases worldwide annually and 27.000 in Spain. Increasingly effective oncology therapies, however, have numerous adverse effects such as muscle degeneration, fatigue, decreased physical function and aerobic capacity, and deteriorating quality of life. In this sense, physical activity (PA) seems to be an interesting non-pharmacological strategy to alleviate these serious complications and with potential benefits for women with BC. Melatonin (N-acetyl-5 methoxytryptamine) is an indolic compound present with pleiotropic bioactions that regulates the circadian rhythm, antioxidant, anti-inflammatory, immunostimulant, cardioprotective, antidiabetic, antiobesity, neuroprotective, and antiaging actions. Furthermore, in recent years, many studies have described the key role of melatonin in preventing and developing cancer. The general anticarcinogenic mechanisms include epigenetic control, cell proliferation modulation, cell cycle regulation, apoptosis induction, and telomerase inhibition. Melatonin also exerts antiestrogenic activity, which is particularly significant in hormone-dependent tumors, regulating the expression and transactivation of the estrogen receptor, and modulating the enzymes involved in the local synthesis of estrogens. Despite all the mentioned properties, the use of melatonin in daily clinical practice is very limited, and additional studies are needed to better establish the role of this hormone in oncological clinical applications against different types of cancer.\n\nObjective: To analyze the effect of supplementation with 4 g\u002Fday of melatonin for 10 weeks on muscle damage (CK and LDH), hormonal responses (estradiol, testosterone, cortisol and testosterone\u002Fcortisol ratio), antioxidant capacity (BAP and d-ROMs), Exerkins (Irisin and Sestrin 2), physical performance (handgrip strength, RPE and SPPB), anthropometry (body mass, BMI and fat mass) and WHOQOL-BREF (physical and psychological health, social relationships and environment) in women over 60 years of age who have suffered breast cancer and who follow a physical training program.\n\nMethods: A total of 20 female volunteers between 60 and 73 years old (age: 65.5±4.52 years, BMI: 25.83±2.67 and body fat percentage: 33.73±5.54) who followed a physical activity adapted to their age and abilities are the members. of this study. The volunteers were divided into two groups: placebo (CG; n = 10) and supplemented with 5 g\u002Fday of melatonin (GI; n = 10). Differtent test were performed muscle damage (CK, and LDH), hormonal responses (estradiol, testosterone, cortisol, and testosterone\u002Fcortisol ratio), antioxidant capacity (BAP and d-ROMs), Exerkins (Irisin and Sestrin 2), physical performance (Hand-grip strength, RPE and SPPB), anthropometrics (Body mass, BMI and fat mass), and WHOQOL-BREF (physical and psychological health, social relationships and environment) were analyzed at the beginning (T1) and at the end of the 10 weeks of intervention (T2).",[27,161,162],"Older Adults","Exercise Trainning Progrmam",[164,165,166,167,168,169,170,171],"Brear Cancer","Melatonin","quality of life","physical performance","health biomarkers","antioxidant capacity","anthropometrics parameters","Exerkins","2024-11-18",{"date":174,"type":34},"2024-11-20",{"date":176,"type":21},"2025-01-15",{"date":178,"type":21},"2026-05-01",{"name":180,"class":41},"University of Valladolid",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":50,"minAge":85,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":42},"100484301","ultra-hypofractionated-radiotherapy-in-breast-cancer-patients-100484301","NCT05586256","Ultra-hypofractionated Radiotherapy in Breast Cancer Patients","Ultra-hypofractionated Adjuvant Radiotherapy After Breast Conserving Surgery in Breast Cancer Patients","Inclusion Criteria:\n\n* Female patients\n* Age ≥ 18 years.\n* Early stage breast cancer treated with breast conserving surgery\n* Whole breast irradiation without regional nodal irradiation\n* Infiltrating carcinomas\n* CDIS\n* Written informed consent\n\nExclusion Criteria:\n\n* Age\\\u003C18 years.\n* Regional nodal radiotherapy.\n* Distant metastases.\n* Previous history of malignancy except basaloid skin tumours and CIN. Previous history of breast cancer is not an exclusion criteria if treated with curative intent and if patient is disease free at least 5 years from diagnosis.\n* Presence of absolute radiotherapy contraindications (pregnancy, inability to maintain the correct treatment position) and relative radiotherapy contraindications (connective tissue diseases including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, dermatomyositis and vasculitis, especially if the disease is in an active phase)\n* Patient's refusal to use data for research purposes.","99 Years",{"count":190,"type":21},300,"The present multicenter, retrospective and prospective observational study, aims to evaluate an ultra-hypofractionated whole breast irradiation schedule (WBI, 26 Gy in 5 fractions), in order to confirm literature data (FAST-F study) in the clinical practice.\n\nPatient population included women affected by early stage breast cancer (BC), both invasive and ductal carcinoma in situ, receiving ultra-hypofractionated WBI (with or without a tumor bed boost) after breast conserving surgery (BCS). Main exclusion criteria are mastectomy and regional nodal irradiation. Neoadjuvant and\u002For adjuvant systemic therapies are allowed. The primary otcome is acute and chronic toxicity evaluation. Secondary outcomes are: overall servival (OS), disease-free survival (DFS), rates of local and loco-regional recurrences, distant metastasis occurrence, cosmetic outcome and quality of life (QoL) assessment. Acute and late toxicities will be scored according to the Common Terminology Criteria for Adverse Events (CTCAE) scale version 5.0. Cosmetic assessment will be graded according to the Harvard scale. Frontal photographs of both breasts will be used to evaluate toxicity and cosmetic results. For QoL assessment the EORTC (European Organisation for Research and Treatment of Cancer), QLQ-C30 and EORTC-QLQ-BR23 questionnaires will be administered.",[27],[194,195,196],"early stage breast cancer","breast conserving surgery","ultra-hypofractionated whole breast irradiation","2022-10-16",{"date":199,"type":34},"2022-10-19",{"date":201,"type":34},"2021-07-21",{"date":203,"type":21},"2026-07-21",{"name":205,"class":41},"University Of Perugia"]